Signaling cascade

A signaling cascade is the ordered chain of molecular events that unfolds inside a cell after a receptor is activated — the mechanism by which a signal at the cell surface is converted into a change in cell behaviour. Because each step can activate many molecules of the next, the cascade amplifies the original signal: a single receptor activation can ultimately alter the activity of hundreds or thousands of downstream molecules.

The term applies broadly to receptors of every type — G protein-coupled receptors (GPCRs), ion channels, receptor tyrosine kinases — but it is especially central to psychopharmacology, where most mood- and perception-altering substances act on GPCRs that couple to several distinct downstream pathways.

How it works · its role

When a ligand binds to a GPCR, the receptor changes shape and activates an attached G protein. The G protein then switches on (or off) enzymes that produce second messengers — small molecules such as cyclic AMP or calcium that carry the signal deeper into the cell. These second messengers activate protein kinases, which phosphorylate further targets, and so on until a physiological response is produced: a neuron fires less, a gene is transcribed, a channel opens.

Different G protein subtypes route signals in opposite directions. The Gs subtype raises cyclic AMP levels and tends to increase neuronal excitability; Gi lowers them, reducing activity. Gq drives a separate arm, releasing calcium from intracellular stores. Which arm a receptor favours depends on its structure and on the specific molecule that has bound it.

This last point matters because receptors do not always activate all their possible downstream pathways equally. A phenomenon called biased agonism (or functional selectivity) describes the ability of different ligands at the same receptor to preferentially engage different cascades — so two drugs binding the same target can produce meaningfully different cellular and subjective effects.

Relevance to substances & effects

Most psychoactive substances work by modulating one or more signaling cascades. Opioids bind μ-opioid receptors, which couple primarily to Gi; the resulting fall in cyclic AMP suppresses neuronal firing and reduces pain signalling, but also slows breathing — both effects are downstream consequences of the same receptor activation. Cannabinoids at CB1 receptors follow a similar Gi route.

Serotonergic psychedelics such as LSD and psilocin act at the 5-HT₂A receptor, which couples to Gq and triggers calcium release. This cascade is thought to underlie the perceptual and cognitive changes of the psychedelic state. Different 5-HT₂A ligands appear to bias the receptor toward different downstream arms, which may partly explain why structurally distinct psychedelics produce different qualitative experiences despite sharing the same primary target.

Because cascades interact — second messengers from one pathway can modify another — combining substances that converge on the same downstream signals can produce effects neither drug generates alone, and can make interactions difficult to predict from either substance's profile in isolation.